|Articles|February 13, 2023
Novavax COVID Vaccine 140 Million Dose Order Canceled by Japan, Takeda Reveals
Takeda's partnership with Novavax to manufacture 150 million doses of COVID-19 vaccine has been heavily impacted.
Advertisement
In 2021, Takeda announced a partnership with Novavax to manufacture 150 million doses of the Nuvaxovid COVID-19 vaccine; however, the Japanese government has canceled its order for the remaining 141.76 million doses due to low demand.
Japan's cancellation of the Novavax vaccine order will not significantly impact Takeda's finances and the company is not altering its full-year consolidated forecasts.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5